NCT00128830 - A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Human Immunodeficiency Virus Type 1

Interventions

DRUG

Etravirine (ETR)

Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.

DRUG

Nucleotide reverse transcriptase inhibitors (NRTIs)

Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).

DRUG

Protease inhibitors (PIs)

Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).

DRUG

Enfuvirtide (ENF)

Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY